PCM
ESLA icon

Pinz Capital Management’s Estrella Immunopharma ESLA Stock Holding History

Pinz Capital Management’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-24,100
Closed -$241K – 125
2022
Q2 		$241K Hold
24,100
– – 0.17% 166
2022
Q1 		$241K Hold
24,100
– – 0.15% 122
2021
Q4 		$239K Buy
+24,100
New +$239K 0.09% 204

Other funds holding ESLA

KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
HHGC
Hunting Hill Global Capital New York $129M AUM 17.34% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Pinz Capital Management's ESLA Position: Q3 2022 in Review

Pinz Capital Management sold out of Estrella Immunopharma (ESLA) in Q3 2022, closing a stake of 24,100 shares — an estimated $241K sold.

Pinz Capital Management first reported a position in ESLA in Q4 2021 and held it in 3 quarters. The position peaked at $241K in Q2 2022. 23 funds tracked by Wall St. Rank hold ESLA as of Q3 2022.

  • Pinz Capital Management reported no remaining Estrella Immunopharma position as of Q3 2022 after selling out during the quarter.
  • Pinz Capital Management sold 24,100 Estrella Immunopharma shares in Q3 2022, an estimated $241K.
  • Pinz Capital Management first reported a position in Estrella Immunopharma in Q4 2021 and held it in 3 quarters.
  • Pinz Capital Management's Estrella Immunopharma position peaked at $241K in Q2 2022.
  • 23 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q3 2022.

Based on Pinz Capital Management's 13F filing for Q3 2022, filed 15 Nov 2022.